title: Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre.
abstract: OBJECTIVE
  To report a retrospective review of patients with a testicular germ cell tumour treated in a large cancer centre who developed a second tumour, as 1.8-5% of such patients will subsequently develop a new primary tumour in the contralateral testis.
  
  
  METHODS
  From a database of 570 men treated for testicular cancer in the West of Scotland between 1989 and 1998, all those who developed bilateral testicular tumours were identified.
  
  
  RESULTS
  Nineteen men (3.3%) developed a second primary testicular malignancy; the mean age at diagnosis of the first tumour was 29.5 years, with the mean (range) interval to diagnosis of the second tumour of 76 (11-181) months (except for one man with synchronous tumours). The first tumour was teratoma in 11 and seminoma in seven; one patient had synchronous bilateral teratoma. The second primary was teratoma in 10 and seminoma in eight. Known risk factors for carcinoma in situ were present in nine patients, i.e. a small atrophic contralateral testis in five, a family history of testicular cancer in two, a history of infertility in two and unilateral undescended testis in one. Two patients had had contralateral testicular biopsies at the first diagnosis; both were negative for intratubular germ cell neoplasia (IGCN). Eight patients had chemotherapy to treat the first tumour and 14 for the second. All underwent bilateral orchidectomy. Overall, 18 of 19 men are alive and disease-free, with a median follow-up of 51 months. Pathology for 12 of the second testicular tumours was available for review; there was no IGCN in any of the slides from three patients, it was only present focally around the tumour in seven, and was diffuse in two patients.
  
  
  CONCLUSIONS
  Chemotherapy for the first testicular tumour does not eliminate the risk of developing a contralateral tumour. Despite careful follow-up, in most patients the second primary tumour was not diagnosed early enough to avoid chemotherapy. The focal nature of IGCN in the second testis in most patients questions the value of biopsy of the contralateral testis. Improved methods of detecting patients at risk of second testicular tumours are needed.
authors.affiliation: The University Department of Urology, Western Infirmary, Gartnavel General, and Stobhill Hospitals, Glasgow, UK. Bpamenter@aol.com
authors.forename: B
authors.initials: B
authors.lastname: Pamenter
authors.forename: J S
authors.initials: JS
authors.lastname: De Bono
authors.forename: I L
authors.initials: IL
authors.lastname: Brown
authors.forename: M
authors.initials: M
authors.lastname: Nandini
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
authors.forename: J M
authors.initials: JM
authors.lastname: Russell
authors.forename: A J
authors.initials: AJ
authors.lastname: Yates
authors.forename: D
authors.initials: D
authors.lastname: Kirk
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005500:Follow-Up Studies; D018237:Germinoma / Q000473:pathology / Q000517:prevention & control* / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000473:pathology / Q000517:prevention & control* / Q000532:radiotherapy; D012189:Retrospective Studies; D012307:Risk Factors; D013736:Testicular Neoplasms / Q000473:pathology / Q000517:prevention & control* / Q000532:radiotherapy